Q2 Earnings Forecast for NeuroPace Issued By Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for shares of NeuroPace in a research note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of ($0.22) per share for the quarter, up from their previous forecast of ($0.23). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.46 EPS.

A number of other equities analysts have also weighed in on NPCE. JPMorgan Chase & Co. boosted their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 14th. HC Wainwright initiated coverage on shares of NeuroPace in a report on Wednesday, May 28th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

NeuroPace Stock Performance

NPCE opened at $12.94 on Monday. The firm has a market capitalization of $424.42 million, a PE ratio of -12.94 and a beta of 2.03. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98. The firm’s 50-day moving average price is $12.90 and its 200 day moving average price is $12.37. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. The firm had revenue of $22.52 million for the quarter, compared to analyst estimates of $21.85 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.

Insider Buying and Selling

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the sale, the insider now directly owns 3,238,199 shares in the company, valued at $51,325,454.15. This represents a 4.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 22.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On NeuroPace

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in NeuroPace during the 4th quarter worth approximately $29,000. GAMMA Investing LLC acquired a new stake in NeuroPace during the 1st quarter worth approximately $53,000. Wells Fargo & Company MN lifted its holdings in NeuroPace by 54.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock worth $73,000 after buying an additional 2,279 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in NeuroPace during the 4th quarter worth approximately $103,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of NeuroPace during the fourth quarter worth approximately $112,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.